| Literature DB >> 32731481 |
Cecilia Jimenez-Lopez1,2, Maria Carpena1, Catarina Lourenço-Lopes1, Maria Gallardo-Gomez3, Jose M Lorenzo4, Francisco J Barba5, Miguel A Prieto1, Jesus Simal-Gandara1.
Abstract
(1) Background: Extra virgin olive oil (EVOO) is responsible for a large part of many health benefits associated to Mediterranean diet as it is a fundamental ingredient of this diet. The peculiarities of this golden, highly valued product are in part due to the requirements that must be met to achieve this title, namely, it has to be obtained using exclusively mechanical procedures, its free acidity cannot be greater than 0.8%, it must not show sensory defects, and it has to possess a fruity taste. (2)Entities:
Keywords: EVOO quality; applications; bioactive substances; chemical composition; extra virgin olive oil
Year: 2020 PMID: 32731481 PMCID: PMC7466243 DOI: 10.3390/foods9081014
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1Scheme of the beneficial and healthy effects of the olive oil inclusion in the Mediterranean diet. Information adapted from [11,12].
Figure 2Summary of the oil extraction process focused on extra virgin olive oil (EVOO) production. The boxes with discontinuous outline refer to the obtainment of other type of oils. Modified from different schemes of [10,17].
Types of olive oils. Modified from EU Council Regulation (EC) No 1234/2007 [15].
| Type of Oil | Characteristics | Free Acidity | |
|---|---|---|---|
|
| EVOO | They are characterized for being obtained by mechanical or other physical processes under specific thermal conditions that do not cause alterations in the oil and have not suffered any treatment other than washing, decantation, centrifugation or filtration. Excluded are oils obtained using solvents or adjuvants with chemical actions, by re-esterification process or any mixture with oils of other types. | <0.8 g per 100 g |
| Virgin olive oil | ≤2 g per 100 g | ||
| Lampante olive oil | >2 g per 100 g | ||
|
| In this case, virgin olive oil is submitted to a refining process. | ≤0.3 g per 100 g | |
|
| It is the result of the blending of the two previous oils: virgin olive oils (not lampante oil) with refined olive oil. | ≤1 g per 100 g | |
|
| This type refers to oil obtained from olive pomace by using solvents, physical treatments or oil corresponding to lampante olive oil type, except for certain specified characteristics. | ||
|
| This type is obtained from refining crude olive pomace oil. | ≤0.3 g per 10 g | |
|
| It if the resultant oil from mixing refined olive pomace oil and virgin olive oil different than lampante oil. | ≤1 g per 100 g | |
NOTES: (1) The International Olive Council (IOC) establishes olive oil standards in terms of sensory analysis and chemical composition for each category. (2) In the case of Lampante oil, it is also referred as “virgin olive oil not fit for consumption” by the IOC and with a free acidity higher than 3.3 g per 100 g.
Figure 3Representative chemical structures of some relevant compounds present in EVOO.
Major EVOO components.
| Component | Concentration | References | |
|---|---|---|---|
|
| |||
| Fatty acids (%) | |||
| Myristic acid | C14:0 | 0.05 | [ |
| Palmitic acid | C16:0 | 9.4–19.5 | [ |
| Palmitoleic acid | C16:1 | 0.6–3.2 | [ |
| Heptadecanoic acid | C17:0 | 0.07–0.13 | [ |
| Heptadecenoic acid | C17:1 | 0.17–0.24 | [ |
| Stearic acid | C18:0 | 1.4–3.0 | [ |
| Oleic acid | C18:1 | 63.1–79.7 | [ |
| Linoleic acid | C18:2 | 6.6–14.8 | [ |
| α-Linolenic acid | C18:3 | 0.46–0.69 | [ |
| Arachidic acid | C20:0 | 0.3–0.4 | [ |
| Eicosenoic acid | C20:1 | 0.2–0.3 | [ |
| Docosanoic acid | C22:0 | 0.09–0.12 | [ |
| Lignoceric acid | C24:0 | 0.04–0.05 | [ |
| MUFA | 65.2–80.8 | [ | |
| PUFA | 7.0-15.5 | [ | |
| Other lipids | |||
| Diacylglycerols (%) | 1–2.8 | [ | |
| Monoacylglycerols (%) | 0.25 | [ | |
| Total sterol content (mg/kg) | 1000–3040 | [ | |
|
| |||
| α- Tocopherol | 10.2–208 | [ | |
| β- Tocopherol | 0.75–1.05 | [ | |
| γ- Tocopherol | 0.7–2.1 | [ | |
|
| |||
| Squalene | 200–8260 | [ | |
|
| |||
| Total chlorophylls (mg/kg) | 0.15–61.96 | [ | |
| Pheophytin-a (mg/kg) | 0.08–0.49 | [ | |
| Total carotenoids (mg/kg) | 0.53–31.51 | [ | |
| β-carotene (mg/kg) | 0.15–0.67 | [ | |
| Lutein (mg/kg) | 0.65–3.60 | [ | |
|
| |||
| Total phenolic compounds (mg/kg) | 213–450 | [ | |
| Triterpene dialcohols (% of total sterols) | 0.9–2.8 | [ | |
| β-sitosterol (mg/kg) | 530.2–2638.6 | [ | |
Main bioactivities associated with EVOO consumption.
| Bioactivity | Studies Description | Main Results | Ref |
|---|---|---|---|
|
| RCT, PREDIMED | Following a MED enriched with EVOO decreases CVD risk by 30% | [ |
| PREDIMED observational study ( | For each 10g EVOO/day intake, CVD risk decreases by 10% | [ | |
| Systematic review of 15 RCTs | 10–50 mL/day EVOO reduced diastolic blood pressure by 0.7 mm Hg | [ | |
| Meta-analysis of 9 studies (38,673 stroke and 101,460 CHD cases from RCT, case-control and prospective studies) | For every increase of 25 g of olive oil consumption the risk of CVD, stroke and CHD was reduced by 18%, 26% and 4% respectively | [ | |
| Meta-analysis of 26 RCTs | High polyphenol olive oil intake significantly reduced CVD and inflammatory markers | [ | |
|
| European Food Safety Authority health claim. | 5 mg/day of olive oils polyphenols protects blood lipids from oxidation | [ |
| RCTs evaluating the effect of olive oils consumption on blood lipids oxidative state. | EVOO and high-phenolic olive oils consumption reduces LDL oxidation in a dose-dependent manner | [ | |
| Controlled trials with sub-samples of PREDIMED cohort ( | Adherence to a MED enriched with EVOO improves HDL function and protects against LDL oxidation | [ | |
| In vitro studies review. | Lignans present in EVOO show antioxidant activity in vitro | [ | |
|
| Meta-analysis of 13 studies based on 9 RCTs | Regular consumption of EVOO reduces IL-6, CRP and TNF-α levels | [ |
| Meta-analysis of RCTs (3106 participants) | Diet supplemented or enriched in olive oil reduces IL-6 and CRP plasmatic levels | [ | |
| Randomized crossover study (49 patients) | High-phenolic virgin olive oil in breakfast reduces postprandial inflammatory response. | [ | |
|
| Meta-analysis of 19 case-control studies (comprising 13,800 cancer cases and 23,340 controls) | Olive oil consumption is associated with lower odds of developing digestive and breast cancers | [ |
| Cohort-study follow up (2321 breast cancer cases and 1665 controls) and meta-analysis | Inverse association between adherence to MED and ERN breast cancer | [ | |
| RCT with a sub-sample of the PREDIMED cohort ( | Women following MED enriched in EVOO showed 62% relatively lower risk of breast cancer compared to control low-fat diet | [ | |
| Systematic review and meta-analysis of 83 studies, comprising a total of 2,130,753 subjects | The adherence to MED is associated with lower risk of cancer mortality and lower risk of breast, colorectal, gastric and liver cancers, among others | [ | |
| In vitro experiments of antitumoral activity of phenolic compounds on cancer cell lines | The phenolic fraction of EVOO, as well as isolated phenolic compounds, shows antitumoral and cytotoxic effect on different cancer cell lines | [ | |
|
| RCT with 12 hypercholesterolemic participants | Virgin olive oil enriched in phenolic compounds consumption favors gut bifidobacteria growth and decreases serum levels of oxidized LDL | [ |
| Systematic review and meta-analysis of 17 RCTs | Polyphenols exert a prebiotic action on gut microbiota, improving also CVD and CRC | [ |
EVOO: extra virgin olive oil; CVD: cardiovascular disease; CHD: coronary heart disease; RCT: randomized controlled trial; MED: Mediterranean diet; HDL: high-density lipoprotein; LDL: low-density lipoprotein; IL-6: interleukin-6; CRP: C-reactive protein; TNF-α: tumor necrosis factor alpha; IBD: inflammatory bowel disease; ERN: estrogen receptor negative; CRC: colorectal cancer.
Figure 4Parameters and factors concerning EVOO quality and its preservation.